Loading stock data…
RLAY
$14.09+0.43 (+3.15%)
After Hours$14.09+0.00 (+0.00%)· Last close Jun 9
Relay Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Relay Therapeutics, Inc. in the Healthcare sector is trading at $14.09 with a market capitalization of $3.3B. Wall Street consensus targets $24.25 (12 analysts), implying a +72.1% move over the next 12 months. The stock is currently 19% below its 52-week high of $17.47, remaining 58.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +72.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$14.09
Potential Downside
0%
Whystock Fair Value$14.09
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$24.25+72.1%
Range$18.00 – $32.00
Fundamentals
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.75
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.47%
Volume
Today's trading volume
2.91M
Recent News
Is Relay Therapeutics a Buy After Promising Trial Results?
Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy.
Relay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data Release
Earlier this week, Relay Therapeutics completed a US$275,000,004 follow-on equity offering at US$12.00 per share, shortly after reporting initial Phase 2 ReInspire data showing that zovegalisib led to a 60% volumetric response rate and broad symptom improvement in patients with PIK3CA-driven vascular anomalies. The results, which highlighted lesion shrinkage in most patients and a safety profile considered suitable for chronic use, underscore Relay’s bid to position zovegalisib as a...
Why Relay Therapeutics Stock Popped on Wednesday
In a way, this was a delayed reaction to excellent news from the lab.
This Biotech's Drug Just Wiped The Floor With Forecasts
Relay Therapeutics wiped the floor Tuesday with Wall Street's expectations for its experimental vascular anomalies treatment.
Sector Update: Healthcare Stocks Rise Tuesday Afternoon
Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State S